Preliminary estimates showed relative bivalent booster dose vaccine effectiveness against XBB/XBB.1.5 for at least the first 3 months after vaccination.
Among the CDC vaccine advisory group's recommendations are adding COVID-19 vaccines to the Vaccine for Children program and allowing PCV20 shots for those who previously received PCV13.
One study showed the boosters provide significant protection against hospitalization and ED care and the other found vaccine effectiveness of 84% in older adults.